Navigation Links
Nanotech medicine, tumor tracking, new technologies and more
Date:7/14/2010

radiation. The drugs can be tailored to different tumor types, the researchers say.

"Right now, these markers are just passive implants that are inserted into the tumor," says Srinivas Sridhar, a physics professor at Northeastern University and director of the university's Electronic Materials Research Institute. "We're making them active and smart using nanotechnology," he said.

The challenge is designing a system that will work over an extended period of time and target the entire tumor without affecting healthy tissue. The team has already developed a nanoscale polymer coating containing anti-cancer drugs for gold fiducials, which are commonly used markers.

Now, the researchers report they can precisely tailor drug dosage and rate of release in laboratory tests lasting up to three months. The nanoporous morphology of the polymer coatings enabled the controlled release of molecules and nanoparticles. The results also help refine the team's models of drug release kinetics.

The group includes collaborators Mike Makrigiorgos and Robert Cormack from Brigham & Women's Hospital and Dana-Farber Cancer Institute.

The Presentation " Release Kinetics of Radio-Sensitizers From Nanoporous Coatings On Gold Fiducials : Biological In-Situ Dose-Painting for IGRT" by C Stambaugh et al. will be at 4:12 p.m. on Wednesday, July 21 in room 204B of the Pennsylvania Convention Center.

ABSTRACT: http://www.aapm.org/meetings/amos2/pdf/49-13246-24612-876.pdf


2) TUMOR TRACKING WITH SMART PROBING A STOCK MARKET APPROACH

Pinpointing tumor location and behavior can be as risky and frustrating as estimating the rise and fall of stocks in the market. A new model, developed by Dan Ruan, Ph.D., an instructor in radiation oncology at Stanford University, and colleagues, employs tactics similar to those used by market analysts. Ruan will p
'/>"/>

Contact: Jason Socrates Bardi
jbardi@aip.org
858-775-4080
American Institute of Physics
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology news :

1. Bionanotechnology has new face, world-class future at Florida State
2. Chemist monitors nanotechnologys environmental impact
3. DNA nanotechnology breakthrough offers promising applications in medicine
4. Vigilance needed in nanotechnology
5. Biotech, nanotech and synthetic biology roles in future food supply explored
6. Engineers explore environmental concerns of nanotechnology
7. Conference to discuss future of nanotechnology enabled sensors
8. Novel nanotechnology heals abscesses caused by resistant staph bacteria
9. Nanotech protection
10. New Singapore-France research alliance to develop state-of-the-art nanotechnologies
11. Step forward for nanotechnology: Controlled movement of molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... For the first time, Spanish researchers have detected an ... coli cells are introduced into a droplet of ... the sodium chloride crystallisation to create biomineralogical biosaline 3D ... rehydrating the material, bacteria are revived. The discovery was ... made the cover of the Astrobiology journal ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... for the body to make estrogen, are no longer a ... Ghosh lab at the Hauptman-Woodward Medical Research Institute (HWI) in ... three-dimensional structure of aromatase is the first time that scientists ... In fact, the Ghosh lab has determined the ...
... shows the resistance of the avian flu virus to a ... selection, with researchers documenting the trend in more than 30 ... Influenza A subtype dubbed H5N1, is evolving a resistance to ... two classes of antiviral drugs used to prevent and treat ...
... drug therapy called fenobam has shown promising initial results and ... with Fragile X syndrome (FXS). Findings of the open ... and the University of California, Davis, Medical Center are to ... Journal of Medical Genetics . Results of ...
Cached Biology News:HWI scientist first in world to unravel structure of key breast cancer target enzyme 2HWI scientist first in world to unravel structure of key breast cancer target enzyme 3Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 2Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 3Promising new drug being evaluated as possible treatment option for fragile X syndrome 2
(Date:7/24/2014)... Although most natural and synthetic processes prefer to ... potential or energyit is within the realm of ... experience constant changes in energy and phases, such ... These conditions allow humans to regulate their body ... rumble with seismic activity. , But even ...
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Genomics and Proteomics Analytical Instruments Market 2014-2018" report ... Genomics is the study of the ... of the structure and functions of proteomes or sets ... and technology. Genomics involves the mapping of genes and ...
(Date:7/24/2014)... 2014 SRI International has been awarded a ... of Allergy and Infectious Diseases (NIAID), part of the ... potential therapies for HIV infection and AIDS. The contract ... AIDS and the complications and opportunistic infections associated with ... transmission of HIV. According to the ...
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... to be semi-finalists in Livestrong’s Big C Competition. Out ... Health are each headed to the semi-final round. In ... Livestrong’s exclusive three-month accelerator program, complete with mentoring from ... , As part of the angelMD commitment to ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2
... /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... CSKI ), a leading,fully integrated pharmaceutical company producing ... today announced that the Company,s,Chief Financial Officer, Mr. ... at the upcoming Roth 21st Annual OC Growth ...
... COTTAGE, N.Y., Feb. 5 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... February 3, 2009 the Company received a letter from ... outstanding ordinary shares requesting the,convening of an extraordinary shareholders, ... address and approve the following matters: , ...
... Va., Feb. 5, 2009 AMERIGROUP Chairman and Chief ... on legislation expanding the State Children,s Health Insurance Program ... of America,s children deserve a healthy start in life, ... see a family doctor and get the healthcare they ...
Cached Biology Technology:China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter 2AMERIGROUP Praises Expansion of State Children's Health Insurance Program (SCHIP) 2
... CL3 series is designed to enhance ... clinical applications at a reasonable cost. ... quick connect rotors and various biocontainment ... interface allows you to control and ...
... tradition of progressive centrifuge design and manufacturing, ... Centra-CL3 and Centra-CL3R (refrigerated) general purpose models ... Quality Control Over Sample Preparation , The ... to 99 protocols and has speed and ...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... DNA Polymerase I Large (Klenow) Fragment, ... that lacks both the 5´→3´ and the ... coli DNA Polymerase I (1,2). It is ... in strand displacement amplification (5). Klenow Fragment, ...
Biology Products: